Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii

被引:39
作者
Averbuch, D
Boekhout, T
Falk, R
Engelhard, D
Shapiro, M
Block, C
Polacheck, I
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Pediat, IL-91120 Jerusalem, Israel
[3] CBS Yeast Div, Utrecht, Netherlands
关键词
antifungal(s); Cryptococcus laurentii; cryptococcosis; fungemia;
D O I
10.1080/714031137
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We report the recent isolation of Cryptococcus laurentii from the blood of a patient given the diagnosis of ganglioneuroblastoma. The organism was identified using physiological and molecular characteristics, including morphology, carbohydrate and nitrate assimilation, urease activity, inability to form melanin on appropriate media, positive staining with diazonium blue B and sequence analysis of the D1/D2 domain of 26S ribosomal DNA. The isolate was resistant to fluconazole and 5-fluorocytosine using both the Etest and a broth microdilution assay. Repeated recovery of the organism from different blood cultures, and the patient's good response to treatment with amphotericin B support its etiological role. C laurentii has rarely been implicated as a cause of clinically significant infections. The identity of reported isolates has not always been adequately documented, and some appear to have been isolated from lesions caused by Cryptococcus neoformans, emphasizing the true rarity of disease due to this fungus.
引用
收藏
页码:479 / 484
页数:6
相关论文
共 31 条
[21]   CRYPTOCOCCOSIS IN THE ERA OF AIDS - 100 YEARS AFTER THE DISCOVERY OF CRYPTOCOCCUS-NEOFORMANS [J].
MITCHELL, TG ;
PERFECT, JR .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :515-&
[22]   FUNGAL PERITONITIS IN CHILDREN ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS [J].
MOCAN, H ;
MURPHY, AV ;
BEATTIE, TJ ;
MCALLISTER, TA .
SCOTTISH MEDICAL JOURNAL, 1989, 34 (04) :494-496
[23]   Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans [J].
Mondon, P ;
Petter, R ;
Amalfitano, G ;
Luzzati, R ;
Concia, E ;
Polacheck, I ;
Kwon-Chung, KJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1856-1861
[24]  
National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[25]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247
[26]  
REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1
[27]   In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts [J].
Ryder, NS ;
Wagner, S ;
Leitner, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1057-1061
[28]   CRYPTOCOCCUS-LAURENTII INFECTION COMPLICATING PERITONEAL-DIALYSIS [J].
SINNOTT, JT ;
RODNITE, J ;
EMMANUEL, PJ ;
CAMPOS, A .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1989, 8 (11) :803-804
[29]   Intraspecies diversity of Cryptococcus laurentii as revealed by sequences of internal transcribed spacer regions and 28S rRNA gene and taxonomic position of C-laurentii clinical isolates [J].
Sugita, T ;
Takashima, M ;
Ikeda, R ;
Nakase, T ;
Shinoda, T .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (04) :1468-1471
[30]  
Vanden Bossche H, 1998, MED MYCOL, V36, P119